| Dr Joel Braun, MD | |
|
1432 S Dobson Rd, Suite 201, Mesa, AZ 85202-4768 | |
| (480) 962-0071 | |
| (480) 962-0590 |
| Full Name | Dr Joel Braun |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 20 Years |
| Location | 1432 S Dobson Rd, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144457110 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081P2900X | Physical Medicine & Rehabilitation - Pain Medicine | 42145 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Progressive Pain Management Inc | 1153490727 | 5 |
| Az Neurosurgery And Spine Pllc | 5294155347 | 2 |
| The Center For Pain And Supportive Care P L L C | 5597847517 | 2 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Entity Name | Robert J. Brownsberger, Md, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013111384 PECOS PAC ID: 9739072216 Enrollment ID: O20040206000873 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Entity Name | Optimal Spine & Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386835965 PECOS PAC ID: 2466487392 Enrollment ID: O20050929000553 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Entity Name | The Center For Pain And Supportive Care P L L C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104009265 PECOS PAC ID: 5597847517 Enrollment ID: O20080130000329 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Entity Name | Progressive Pain Management Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881866754 PECOS PAC ID: 1153490727 Enrollment ID: O20080522000123 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Entity Name | Advanced Minimally Invasive Surgical |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295056919 PECOS PAC ID: 4183758527 Enrollment ID: O20100819001272 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Entity Name | Maria Gonzalez Berlari Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699025981 PECOS PAC ID: 2769625854 Enrollment ID: O20130820001092 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Entity Name | Northern Arizona Spine And Pain Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871918698 PECOS PAC ID: 2466677968 Enrollment ID: O20140625001049 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Entity Name | Hope Diabetes Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104865757 PECOS PAC ID: 4183620487 Enrollment ID: O20170719003937 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Entity Name | Az Neurosurgery & Spine Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578179735 PECOS PAC ID: 5294155347 Enrollment ID: O20201012002084 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Entity Name | Aurora Medical Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699441683 PECOS PAC ID: 7517344872 Enrollment ID: O20220507000240 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joel Braun, MD 1432 S Dobson Rd, Suite 201, Mesa, AZ 85202-4768 Ph: (480) 962-0071 | Dr Joel Braun, MD 1432 S Dobson Rd, Suite 201, Mesa, AZ 85202-4768 Ph: (480) 962-0071 |
News Archive
Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer's. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications.
Most cancer patients who had no measurable immune response after being fully vaccinated for COVID-19 were helped by a third vaccine dose, according to a new study by investigators at the Montefiore Einstein Cancer Center.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Fundamental research undertaken under the supervision of Professor Ute Hellmich of Johannes Gutenberg University Mainz has revealed a promising strategy to develop a suitable agent.
Researchers from the Canada North Concussion Network in Manitoba investigated the frequency of vestibulo-ocular dysfunction in children and adolescents with sports-related concussion and found that its presence was predictive of a prolonged recovery.
Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.
› Verified 8 days ago
Christopher Michael Seare, PT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 2437 E Florian Ave, Mesa, AZ 85204 Phone: 480-613-6535 | |
Dr. Daniel Lev Ryklin, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2045 S Vineyard, Suite 131, Mesa, AZ 85210 Phone: 480-986-7246 Fax: 480-986-7252 | |
Dr. Tutankhamen A Pappoe, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 650 W Southern Ave, 2, Mesa, AZ 85210 Phone: 480-844-3648 Fax: 480-844-9363 | |
Ms. Harla M Ryder, L.M.T Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1945 E Nielson Ave, Mesa, AZ 85204 Phone: 480-234-8982 | |
John Lopez, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 5652 E Baseline Rd, Mesa, AZ 85206 Phone: 480-567-0350 | |
Mr. Blair J Packard Ii, PT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 217 S 63rd St, Ste 101, Mesa, AZ 85206 Phone: 480-981-0900 Fax: 480-981-0897 |